Aripiprazol (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Aripiprazol" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

1,169^th place

914^th place

49^th place

103^rd place

1^st place

low place

doi.org

Lawler CP (1999). „Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes”. Neuropsychopharmacology. 20 (6): 612—27. PMID 10327430. doi:10.1016/S0893-133X(98)00099-2.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005). „Intrinsic Efficacy of Antipsychotics at Human D₂, D₃, and D₄ Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D₂/D₃ Partial Agonist”. J Pharmacol Exp Ther. 315 (3): 1278—87. PMID 16135699. doi:10.1124/jpet.105.092155.
Jordan, S (2002). „The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”. Eur J Pharmacol. 441 (3): 137—140. PMID 12063084. doi:10.1016/S0014-2999(02)01532-7.
Shapiro, DA (2003). „Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology”. Neuropsychopharmacology. 28 (8): 1400—1411. PMID 12784105. doi:10.1038/sj.npp.1300203.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006). „Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms”. Biochem Pharmacol. 71 (4): 521—9. PMID 16336943. doi:10.1016/j.bcp.2005.11.007.

„Abilify (Aripiprazole) - Clinical Pharmacology”. DrugLib.com. 14. 2. 2007. Архивирано из оригинала 22. 05. 2008. г. Приступљено 8. 12. 2008.

Lawler CP (1999). „Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes”. Neuropsychopharmacology. 20 (6): 612—27. PMID 10327430. doi:10.1016/S0893-133X(98)00099-2.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005). „Intrinsic Efficacy of Antipsychotics at Human D₂, D₃, and D₄ Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D₂/D₃ Partial Agonist”. J Pharmacol Exp Ther. 315 (3): 1278—87. PMID 16135699. doi:10.1124/jpet.105.092155.
Jordan, S (2002). „The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”. Eur J Pharmacol. 441 (3): 137—140. PMID 12063084. doi:10.1016/S0014-2999(02)01532-7.
Shapiro, DA (2003). „Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology”. Neuropsychopharmacology. 28 (8): 1400—1411. PMID 12784105. doi:10.1038/sj.npp.1300203.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006). „Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms”. Biochem Pharmacol. 71 (4): 521—9. PMID 16336943. doi:10.1016/j.bcp.2005.11.007.

Keating, Gina (23. 11. 2009). „FDA OKs Abilify for child autism irritability”. Reuters. Приступљено 22. 9. 2010.

„Abilify (Aripiprazole) - Clinical Pharmacology”. DrugLib.com. 14. 2. 2007. Архивирано из оригинала 22. 05. 2008. г. Приступљено 8. 12. 2008.

Hitti, Miranda (20. 11. 2007). „FDA OKs Abilify for Depression”. WebMD. Приступљено 8. 12. 2008.